The Impact of Thyme and Rosemary on Prevention of Osteoporosis in Rats

Amr S. Elbahnasawy 1,2, E. R. Valeeva 1, Eman M. El-Sayed 2, and I. I. Rakhimov 1

1 Department of Bioecology, Hygiene and Public Health, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
2 Department of Nutrition and Food Sciences, National Research Centre, Dokki, Giza, Egypt

Correspondence should be addressed to Amr S. Elbahnasawy; amelbahnasavi@stud.kpfu.ru

Received 7 November 2018; Accepted 26 February 2019; Published 31 March 2019

Academic Editor: Phillip B. Hylemon

Copyright © 2019 Amr S. Elbahnasawy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Osteoporosis is a skeletal disease described by a decrease in bone mass and bone mineral density in addition to bone degradation, which may increase bone fracture risk and skeleton frailty and induce dangerous difficulties [1]. In 2010, more than 99 million persons in USA were estimated to have osteoporosis or low bone mass, and this number is expected to increase by 19% by 2020 and by 32% by 2030 [2]. Calcium is an essential component in bone formation and is considered as the key element of hydroxyapatite, and its use as a therapy for bone resorption is evaluated [3]. Improving the dietary intake of calcium is a nutritional target to prevent osteoporosis [4].

Bone resorption sorely affects public health, and there is no effective and secure way to restore lost bone; many pharmacological drugs, such as denosumab, risedronate, alendronate, and bisphosphonates, are used for treatment of osteoporosis. However, the medications most commonly used are not suitable to take and action is often weak [5]. In addition, many patients avoid taking the medicines because of worry about side effects such as nausea, dizziness, sickness, and sore of the gastrointestinal tract [6].
The role of nutrition in bone formation is quite significant. Choosing a balanced diet with high nutritional value can significantly contribute to enhance skeletal health. Appropriate food is an essential element for bone health, resulting in the treatment and prevention of bone diseases [7]. However, many medicinal herbs prevent osteoporosis and treat bone resorption [8, 9]. Polyphenols extracted from plants attract big attention due to their antimicrobial and antioxidant activities [10]. Phenolic compounds have a valuable free-radical scavenging property, which is determined by their reactivity with other antioxidants compounds and their metal chelating activities [11].

Thyme (Thymus vulgaris L.) is a medicinal herb containing many volatile compounds and essential oils and is widely used worldwide and considered to have potential protective impact against bone loss [12]. The essential oils are nontoxic and biodegradable compounds with antimicrobial activity and without side effects or intestinal troubles after eating [13]. Thyme essential oil consists mainly of thymol, carvacrol, α-pinene, and β-carvophyllene [14]. It has been confirmed that the biochemical impacts of thymus vulgaris are primarily due to the existence of phenolic compounds, especially thymol and carvacrol [15].

Rosemary (Rosmarinus officinalis L.) is supposed to be one of the most important herbs that has many medical benefits, the main volatile compounds are 1,8-cineole, camphor, α-pinene, and α-terpineol [16]. Rosemary is widely used as a flavoring agent in food industries [17]. However, rosemary has potential pharmaceutical benefits in prevention and treatment of many public health issues [18–20]. The aim of the present work is to investigate the inhibitory impact of thyme and rosemary against osteoporosis in rats with calcium deficiency.

2. Materials and Methods

2.1. Plant Materials. Fresh dry herbs of rosemary (Rosmarinus officinalis L.) and thyme (Thymus vulgaris L.) were obtained from the Medicinal and Aromatic Plant Unit, National Research Centre, Cairo, Egypt. The dried leaves were ground to obtain a fine powder.

2.2. Isolation and Analysis of Volatile Compounds of Rosemary and Thyme. Rosemary and thyme were subjected to hydrodistillation for 3 hours using Clevenger-type apparatus for isolation of the essential oil in fresh herbs. The obtained oil of each sample was dried over anhydrous sodium sulfate [21]. The collected essential oils were immediately analyzed using gas chromatography (GC) analysis which was performed by using a PerkinElmer autosystem XL equipped with a flame ionization detector (FID). A fused silica capillary column DB5 (60 m x 0.32 mm id) was used. The oven temperature was maintained initially at 50°C for 5 min and then programmed from 50 to 250°C at a rate of 4°C/min. Helium was used as the carrier gas at flow rate 1.1 ml/min. The injector and detector temperatures were 220 and 250°C, respectively. The retention indices (Kovats index) of the separated volatile components were calculated using hydrocarbons (C8–C22, Aldrich Co.) as references.

2.3. Experimental Animals and Diets. Thirty-five growing male Sprague–Dawley rats weighing 70 ± 10 g, aged 28 days were obtained from the laboratory animal house, National Research Centre, Egypt. The animals were housed individually in stainless steel cages in a controlled environment (25 ± 2°C, 50–60% relative humidity, and 12-hour light-dark cycle), and the experiment lasted for 8 weeks. The animals had ad libitum access to food and deionized water and were subdivided into five groups (7 rats each) as follows: group 1: control negative (C−) was fed standard balanced diet AIN-93G with normal calcium level (0.5% w/w) according to formula described by Reeves et al. [22]; group 2: control positive (C+) was fed balanced diet with low calcium level (L Ca) (Ca 0.1% w/w) according to Shinoki and Hara [23]; group 3: thyme (T) was given L Ca diet and treated with thyme power (5% w/w) [24]; group 4: rosemary (R) was given L Ca diet and treated with rosemary power (5% w/w) [25]; group 5: oral calcium (O) was orally administered with CaCO3 (27 mg/kg b.w.) and fed L Ca diet [26].

2.4. Biochemical Analyses. At the end of experiment, the rats were fasted overnight, blood samples were collected in heparinized tubes, and centrifuged at 2500 rpm under cooling for 15 min to separate the plasma which was subjected to different assays. Plasma calcium (Ca), phosphorus (P), and magnesium (Mg) levels were determined using colorimetric assay kits (BioSystems S.A., Costa Brava, Barcelona, Spain). Plasma tumor necrosis factor-alpha (TNF-α) measurements were assayed using an enzyme-linked immunosorbent assay (ELISA) kit by the RayBio® Rat TNF-α (RayBiotech, Inc., Norcross, Georgia, USA); the assay of C-reactive protein (CRP) was quantitatively determined by the reagent CRP Turbilatex agglutination assay kit (Spinreact, Girona, Spain); Malondialdehyde (MDA) was determined according to the method of Draper and Hadley [27], based on the reaction of MDA with thiobarbituric acid (TBA). Parathyroid hormone (PTH) was measured in plasma using the ELISA kit (MyBiosource, Inc., San Diego, USA). The C-terminal telopeptide (CTX) was assessed using Plasma Cross Laps One-Step ELISA (Osteometer BioTech, Herlev, Denmark). 1,25-(OH)2-Vitamin D3 was quantitatively determined in plasma using ELISA kit (IBL International GmbH, Hamburg, Germany).

2.5. Femur Mass, Length, and Bone Mineral Density. The right femur of each sacrificed rat was dissected out, stripped of all soft tissues, and washed in saline. The femur mass was recorded using electronic balance, and the length was determined with electronic caliper. The bone mineral density of right femur in each group was measured by dual-energy X-ray absorptiometry (DEXA) (Norland XR-600).

Journal of Nutrition and Metabolism
2.6. Histopathological Examination. Femurs were fixed in 10% formalin in saline solution for 48 h and then decalcified in daily exchanges of EDTA. Each sample was then processed to obtain 6-μm-thick paraffin sections to be stained with hematoxylin and eosin stains (H&E) for light microscopic histopathological examination according to the method described by Bancroft and Gamble [28].

2.7. Statistical Analysis. All values are presented as mean ± standard error (SE); one-way completely randomized analysis of variance (ANOVA) used to compare the difference in values in all experimental groups by Tukey’s honestly significant difference (HSD) post hoc test to clarify the significance with significance level (p < 0.05) using the CoStat Version 6.451 statistical program (CoHort Software, USA).

3. Results

The volatile compounds in the hydrodistilled oil of rosemary were identified and cited with their relative area percentage (Table 1). Among the identified compounds 1,8-cineole was the major component (46.69%) followed by camphor (26.30%), α-pinene (5.63%), and α-terpineol (5.23%). The separated volatile compounds of thyme were identified and cited with their relative area percentage (Table 2). Thymol was the predominant compound (73.61%) followed by carvacrol (4.97%) and p-cymene (4.06%).

As presented in Table 3, supplementation with thyme and rosemary significantly increased plasma calcium levels in both T and R groups (8.92 ± 0.13 and 8.54 ± 0.11) compared to the positive control group (7.57 ± 0.12); on the other hand, magnesium and phosphorus levels had no significant changes among all groups. Concomitantly, the inflammatory biomarkers TNF-α and CRP were also estimated as shown in Table 3. Attenuated significant levels of TNF-α compared to positive groups (75.24 ± 0.93) were observed in both T and R groups (47.57 ± 0.96 and 44.53 ± 0.98), respectively. However, these levels were significantly higher than normal control (31.60 ± 0.94). The inflammatory level of CRP in the positive control group was significantly higher than that of the normal control (0.85 ± 0.09) and O group (0.82 ± 0.08). Treatment with thyme maintained the level of CRP in group T (0.97 ± 0.08) with no significant difference compared to normal group. As a marker of lipid peroxidation and oxidative stress, the MDA level was assayed (Table 3); malondialdehyde levels were significantly increased in the control group (2.42 ± 0.11) compared to both the normal control and O groups (1.33 ± 0.10 and 1.44 ± 0.10); otherwise, treatment with herbs significantly improved these levels in T and R groups (1.92 ± 0.12 and 1.85 ± 0.11).

The bone resorption marker CTX levels also were significantly improved by supplementation in both T and R groups (379.71 ± 5.58 and 392.12 ± 7.24) compared to the positive control (507.92 ± 5.76). On the other hand, the vitamin D3 levels in treated groups T and R was significantly increased compared to positive control (46.84 ± 1.07), but these levels were lower than observed in the control normal group (64.12 ± 1.06) and O group (59.05 ± 1.03) (p < 0.05) (Table 3). Furthermore, the PTH level was significantly higher in the control positive group (69.11 ± 1.11) than in both of those intervention groups T and R (50.13 ± 0.94 and 58.87 ± 1.01b), which showed difference from each normal control (45.29 ± 0.92) and oral group (41.21 ± 0.80) (p < 0.05).

Femur mass, length, and bone mineral density are shown in Table 4; groups R and O showed no significant changes in femur mass (3.01 ± 0.17 and 3.16 ± 0.07), respectively, compared to the normal control group (3.02 ± 0.07); otherwise, group T showed insignificant value (2.93 ± 0.12) compared to the positive control (2.46 ± 0.11), which recorded the lowest value among all groups (p < 0.05). On the other hand, femur length had no significant differences among all groups. The intervention with herbs caused a significant improvement in BMD in groups T

### Table 1: Chemical compositions of rosemary essential oils.

| Component         | Kovats index | Area (%) |
|-------------------|--------------|----------|
| α-Pinene          | 937          | 5.63     |
| Camphene          | 953          | 2.13     |
| β-Mycene          | 981          | 0.31     |
| α-Phellandrene    | 990          | 0.50     |
| β-Phellandrene    | 1028         | 1.89     |
| Limonene          | 1033         | 1.34     |
| 1,8-Cineole       | 1037         | 46.69    |
| Terpinolene       | 1100         | 1.39     |
| Camphor           | 1153         | 26.30    |
| Isoborneol        | 1167         | 0.18     |
| Borneol           | 1172         | 0.88     |
| Terpin-4-ol       | 1183         | 0.80     |
| α-Terpineol       | 1196         | 5.23     |
| Verbenene         | 1216         | 0.48     |
| Bornyl acetate    | 1289         | 0.66     |
| β-Caryophyllene   | 1432         | 0.50     |
| δ-Cadinene        | 1517         | 2.04     |

### Table 2: Chemical compositions of thyme essential oils.

| Component         | Kovats index | Area (%) |
|-------------------|--------------|----------|
| α-Pinene          | 937          | 0.27     |
| α-Phellandrene    | 990          | 0.28     |
| α-Terpineol       | 1019         | 0.36     |
| p-Cymene          | 1027         | 4.06     |
| γ-Terpineol       | 1061         | 2.49     |
| Linalool          | 1099         | 0.45     |
| Terpinen-4-ol     | 1182         | 0.41     |
| α-Terpineol       | 1196         | 0.18     |
| Thymol methyl ether | 1235     | 0.33     |
| Carvacrol         | 1245         | 0.28     |
| Bornyl acetate    | 1286         | 0.21     |
| Thymol            | 1296         | 73.61    |
| Carvacrol         | 1304         | 4.97     |
| β-Caryophyllene   | 1432         | 3.33     |
| α-Humulene        | 1470         | 0.38     |
| δ-Cadinene        | 1524         | 0.45     |
| δ-Amorphene       | 1531         | 0.65     |
| Caryophyllene oxide | 1599     | 3.62     |
| Epi-α-cadinol     | 1653         | 1.29     |
Ca (mg/dl) & 9.62 ± 0.13a & 7.57 ± 0.12d & 8.92 ± 0.13bc & 8.54 ± 0.11c & 9.33 ± 0.12ab \\
P (mg/dl) & 4.58 ± 0.12a & 4.67 ± 0.11a & 4.45 ± 0.12a & 4.39 ± 0.12a & 4.51 ± 0.13a \\
Mg (mg/dl) & 1.79 ± 0.10a & 1.82 ± 0.10a & 2.02 ± 0.11a & 1.85 ± 0.11bc & 1.91 ± 0.10a \\
MDA (μmol/l) & 1.33 ± 0.10d & 2.42 ± 0.11a & 1.92 ± 0.12b & 1.92 ± 0.11bc & 1.44 ± 0.10cd \\
TNF-α (pg/ml) & 31.60 ± 0.10d & 2.42 ± 0.11a & 1.92 ± 0.12b & 1.92 ± 0.11bc & 1.44 ± 0.10cd \\
CRP (mg/l) & 64.12 ± 1.06a & 46.84 ± 1.07d & 55.17 ± 0.99bc & 52.83 ± 0.98c & 59.05 ± 1.03b \\
Vitamin D3 (pg/ml) & 45.29 ± 0.92d & 69.11 ± 1.11a & 50.13 ± 0.96c & 58.87 ± 1.01b & 41.21 ± 0.80e \\
CTX (pg/ml) & 4.58 ± 0.12a & 4.67 ± 0.11a & 4.45 ± 0.12a & 4.39 ± 0.12a & 4.51 ± 0.13a \\
PTH (pg/ml) & 1.79 ± 0.10a & 1.82 ± 0.10a & 2.02 ± 0.11a & 1.85 ± 0.11bc & 1.91 ± 0.10a \\

All values are presented as mean ± SE. Means with different letters in each row are significantly different (p < 0.05).

**Table 4: Femur mass, length, and bone mineral density of rats in different experimental animals.**

| Parameters                  | Groups       | Group 1C− | Group 2C+ | Group 3T | Group 4R | Group 5O |
|-----------------------------|--------------|-----------|-----------|----------|----------|----------|
| Femur mass (g/kg body weight)|              | 3.02 ± 0.07a | 2.46 ± 0.11b | 2.93 ± 0.12ab | 3.01 ± 0.17a | 3.16 ± 0.07a |
| Femur length (mm)            |              | 33.7 ± 0.35a | 32.2 ± 0.45a | 32.8 ± 0.59a | 31.8 ± 0.50a | 33.5 ± 0.52a |
| BMD (g/cm²)                  |              | 0.1493 ± 0.0041ab | 0.0981 ± 0.0037c | 0.1357 ± 0.0051ab | 0.1305 ± 0.0064b | 0.1525 ± 0.0051a |

All values are presented as mean ± SE. Means with different letters in each row are significantly different (p < 0.05).

The histopathological examination of the femur of rats from thyme group (T) revealed evident no histopathological changes and normal bone cortex (Figure 1) as in both groups normal control (C−) (Figure 2) and oral calcium group (O) (Figure 3); otherwise, group (R) showed thick bony trabeculae with few cracks in the cortical bone (Figure 4). In contrast, several resorption cavities and thin cortical bone with presence of cracks and fissures as well as dilatation of marrow cavity were seen in the positive control group (Figure 5).

**4. Discussion**

Osteoporosis is the most widespread bone disorder, and its prevalence is expected to increase dramatically in the coming years, treatment of osteoporosis is still a big challenge, and therefore, it is seriously considered as a public health issue [29]. Calcium is an essential mineral that is connected to many metabolic interactions which provide mechanical solidity to the skeleton and teeth, where 99% of the body’s calcium remains; the calcium in bones has the function of acting as a reserve supply of calcium to meet the body’s metabolic requirements in the situation of calcium deficiency [30]. Calcium deficiency easily happens as a result of low calcium intake in diet and losses of calcium via the bowel and kidneys, and it may weaken the growth and delay consolidation of skeleton. Furthermore, calcium deficiency causes mobilization of bone and leads to osteoporosis and a reduction in bone minerals density [30]. The calcium requirement of human may be described as the average calcium intake needed to maintain calcium homeostasis to meet the significant obligated losses of calcium through the gastrointestinal tract, skin, and kidneys [31]. Therefore, the
The aim of this work was to evaluate the capability of thyme and rosemary to counteract osteoporosis and calcium deficiency on the bone microstructure, mineral content, and some biochemical markers in rats.

In our evaluation of herbs looking for active compounds for health and bone metabolism, we found that thymol was the main component of the essential oil of thyme. Some studies in Spain, Poland, and Italy reported that major compounds in thyme essential oil were thymol and $p$-cymene [32–35]. Borugá et al. [36] reported that thymol was the major component in the essential oil of Thymus vulgaris followed by $\gamma$-terpinene and $p$-cymene. Thymol is a monoterpene and considered as one of the most important dietary constituents in thyme species, and it has been used in traditional medicine; it possesses various pharmacological properties including anti-inflammatory, free-radical scavenging, analgesic, antimicrobial, and antispasmodic [37, 38]. The combination of carvacrol and thymol reduced the oxidative stress by their potent antioxidant activity [39]. It has been shown that thymol attenuates apoptosis and lipid peroxidation [40, 41].

After determination of essential oil of rosemary, we found that the main components were 1,8-cineole and camphor, and these results are in quite agreement with those reported by Boutekedjiret et al. [42] and Sienkiewicz et al. [43]. Among the herbs known for medicinal value, rosemary is highly regarded for its therapeutic potentials. Rosmarinus officinalis L. essential oil contains many biologically active compounds, and it confers antibacterial, anti-inflammatory, antioxidant, and pharmaceutical properties [44, 45]. Eucalyptol (1,8-cineole) has several drug properties that have developed an increasing medical interest and evidence of its anti-inflammatory and antioxidant mode of action [46]. Juergens et al. [47] found that 1,8-cineole is a strong inhibitor of cytokines with a surprising improvement in the anti-inflammatory activity.

Sapkota et al. [48] investigated the role of thymol in osteoclastogenesis and bone loss in mice and reported that thymol inhibited osteoclast activity, suppressed bone resorption, and protected against bone loss and pro-inflammatory cytokines; the applications of thymol significantly reduced inflammatory bone loss, and these studies identified that thymol could be a useful therapeutic agent for preventing bone serious diseases. Muhlbauer et al. [12] investigated essential oil extracted from rosemary and thyme and their monoterpene components such as eucalyptol (1,8-Cineole), camphor, borneol, thymol, $\alpha$-pinene, and bornyl acetate; these active compounds inhibit bone resorption when added to the food of rats. The monoterpens borneol, thymol, and camphor are direct inhibitory for osteoclast resorption, and they suggested that these compounds inhibit bone resorption by acting directly on bone cells by influencing calcitropic hormones or via stimulating the intestinal calcium absorption.

The present work indicated that the levels of plasma calcium in rats which were fed low calcium diet were significantly lower than the normal control group, and these results agree with Tannenbaum et al. [49] who recorded that the low intake levels of calcium leads to calcium deficiency in blood and increases the availability to induce osteoporosis. The obtained data suggested that the supplementation with thyme and rosemary in low calcium diet is marked by improving intestinal calcium absorption and may lead to prevent or decrease bone loss and restore the decreased levels of plasma Ca to normal values. These suggestions are in the same line with Banu et al. [50] who found that some herbs had an impact on bone metabolism including thyme and red clovers, they improved the absorption of calcium from the gastrointestinal tract, and they have an arraying effect to keep the calcium homeostasis.

Nutritional factors clearly take a part in the link between inflammation and osteoporosis, and the concordance of
osteoarthritis and inflammation is supported by emerging molecular evidence of mediating immunological factors [51]. Advanced understanding of the bone remodeling process proposes that factors engaged in inflammation are linked with those critical for bone physiology and remodeling [52, 53]. Furthermore, one intriguing aspect of immune ageing is the raised production of proinflammatory cytokines with osteoporosis is well documented [54]. Some inflammatory markers seen in conditions such as rheumatoid arthritis, osteoporosis, and osteomyelitis are typically associated with inflammation. Pro-osteoclastic cytokines, such as tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6), are increased in these conditions, and local cytokine profile is consistent with the cytokines that regulate bone resorption [55, 56]. There is a strong correlation between bone resorption or bone loss in healthy pre- and postmenopausal women and the production of IL-6, and TNF-α by peripheral blood monocytes [57]. C-reactive protein production in the liver is controlled by IL-1, IL-6, and TNF-α and is considered as a sensitive marker of systemic inflammation [58, 59]. A relationship between CRP level and bone mineral density has been proved in many inflammatory diseases, as well as in healthy humans, suggesting a correlation between subclinical systemic inflammation and bone loss [60]. Our results showed that thyme and rosemary have strong effect against inflammation and oxidative stress, and thyme is traditionally used for its antispasmodic and antiseptic actions. Furthermore, thyme has many activities against microbes, fungi, and viruses and also has antioxidative properties [61–63]. The essential oil of thyme is a mixture of monoterpenes, and one of the major components of this oil is thymol [64]. Thymol shows many biological properties including antioxidant [65], anti-inflammatory [66], and free-radical scavenging properties [67]. Rosemary is known to be used in traditional medicine all over the world, and the pharmacological and medical properties of rosemary include anti-inflammatory and antioxidant activities [68, 69]. Lian et al. [70] demonstrated that rosemary essential oils significantly decrease the levels of TNF-α in blood.

In the current study, malondialdehyde was significantly increased in the positive control rats, indicating raise in oxidative stress in these calcium-deficient rats. This result was further confirmed through the finding of elevated levels of malondialdehyde in case of bone resorption, indicating high level of free radicals generation and oxidative stress due to calcium deficiency [71]. The antioxidant of rosemary essential oils is considered as one of the herbs which contains high antioxidant properties [72], and many compounds have been isolated from rosemary, including terpenes, flavones, and steroids [73].

In addition to the improvement of bone formation, our data have shown a decrease in bone resorption as reflected by a decrease in plasma CTX levels by thyme and rosemary supplementation. Addition of thyme and rosemary had decreased CTX levels, and this response seems to be antiresorptive effect of the herb supplementation as there were elevated levels of CTX of positive control; some researches demonstrated that essential oils and their monoterpenes components from common herbs and vegetables affect bone metabolism when added to the food of rats [74]. Clinical studies have shown that CTX are sensitive markers of bone loss [75, 76].

Our data showed a significant increase in vitamin D3 and decrease in PTH levels after treatment with herbs compared to positive control rats. We suggest that, with calcium deficiency in blood, the body tries to restore normal calcium levels. This often leads to an increase in the PTH level in blood, as the parathyroid glands must raise the PTH secretion in order to elevate calcium levels in blood by getting it from bones. Therefore, people with low calcium levels in blood and a high PTH levels may have secondary hyperparathyroidism, which means that the elevated level of PTH is a normal response of healthy parathyroid glands to another issue like calcium insufficiency. It is common in human to have both primary hyperparathyroidism and insufficiency of vitamin D, since primary hyperparathyroidism can lead to decreased vitamin D stores; these observations were in the same line with Berlin and Bjorkhem [77] who demonstrated that an increase in calcium intake in rats causes a reduction in the serum PTH level with a subsequent decrease in 1α-hydroxylase of 25-hydroxyvitamin D3, leading to raise level of 25-hydroxyvitamin D3 as a hypothetical result of suppression the action of the 25-hydroxylase. In a different study, supplementation with calcium increased the levels of 25(OH)D3 in blood significantly over 6 to 7 weeks in 28 healthy youths studying in Sweden during the winter season [78].

In the current study, diets supplemented with rosemary and thyme exhibited positive effects on BMD. The obtained results agree with the findings of Mühlbauer et al. [12] who found that bone loss was suppressed by the essential oils of these herbs; the monoterpenes and essential oil extracts act directly on bone cells through inhibition of the mevalonate pathway and the prenylation of small G-proteins such as Rac and Rho to inhibit bone resorption. Also, the positive effects of flavonoids on bone formation and BMD were studied [79, 80]. Our data showed that femur mass was decreased due to calcium deficiency in the positive control. Hunt et al. [81] found that low calcium levels significantly reduced bone mass and impaired morphology and biomechanical properties of bone in growing rats.

Our histopathological examination reflects all results obtained from biochemical parameters and femur BMD. The femur is considered to be one of the most remarkable skeletal parts in osteoporosis. The human and rat femurs have many common characters between each other at both the macrostructural and microstructural levels [82]. For these reasons, this skeletal site has got great attention and special importance in osteoporosis studies [83]. The balance between osteoblastic bone formation and osteoclastic bone resorption controls bone homeostasis. Osteoporosis occurs as a result of high bone turnover with a rate of osteoclastic resorption higher that of osteoblastic formation, resulting in a reduction of bone mass and impairment of histological characters of bones [84].

5. Conclusion

Our results clearly show that essential oils and monoterpenes of thyme and rosemary, which are widely used as
food additives and in various medical applications, are effective inhibitors of bone resorption and have numerous benefits on bone formation and against inflammation. However, thyme has more protective effect than rosemary against bone resorption and osteoporosis.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments
The authors would like to express their deepest thanks and gratitude to Dr. Amany Hegazy, Ph.D., Department of Nutrition and Food Sciences, National Research Centre, Dokki, Giza, Egypt, for her cooperation, guidance, valuable comments, and continuous encouragement throughout this work. The work was performed according to the Russian Government Program of Competitive Growth of Kazan Federal University. This study was financially supported in part by the Cultural Affairs and Missions Sector, Ministry of Federal University. The work was performed according to the Russian Government Program of Competitive Growth of Kazan Federal University. This study was financially supported in part by the Cultural Affairs and Missions Sector, Ministry of Higher Education (Egypt), National Research Centre (Egypt), and Kazan Federal University (Russian Federation).

References
[1] J. P. van den Bergh, T. A. van Geel, and P. P. Geusens, “Osteoporosis, frailty and fracture: implications for case finding and therapy,” Nature Reviews Rheumatology, vol. 8, no. 3, pp. 163–172, 2012.
[2] N. C. Wright, A. C. Looker, K. G. Saag et al., “The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine,” Journal of Bone and Mineral Research, vol. 29, no. 11, pp. 2520–2526, 2014.
[3] A. Flynn, “The role of dietary calcium in bone health,” Proceedings of the Nutrition Society, vol. 62, no. 4, pp. 851–858, 2003.
[4] X. Deprez and P. Fardellone, “Nonpharmacological prevention of osteoporotic fractures,” Joint Bone Spine, vol. 70, no. 6, pp. 448–457, 2003.
[5] C. A. Inderjeeth, A. J. Inderjeeth, and W. D. Raymond, “Medication selection and patient compliance in the clinical management of osteoporosis,” Aust Fam Physician, vol. 45, no. 11, pp. 814–817, 2016.
[6] S. Khosla, J. A. Cauley, J. Compston et al., “Addressing the crisis in the treatment of osteoporosis: a path forward,” Journal of Bone and Mineral Research, vol. 32, no. 3, pp. 424–430, 2016.
[7] C. Cooper, B. Dawson-Hughes, C. M. Gordon, and R. Rizzoli, Healthy Nutrition, Healthy Bones: How Nutritional Factors Affect Musculoskeletal Health Throughout Life, International Osteoporosis Foundation, Nyon, Switzerland, 2015.
[8] Z. Q. Wang, J. L. Li, Y. L. Sun et al., “Chinese herbal medicine for osteoporosis: a systematic review of randomized controlled trails,” Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 356260, 11 pages, 2013.
[9] J. B. He, M. H. Chen, and D. K. Lin, “New insights into the tonifying kin herbs and formulas for the treatment of osteoporosis,” Archives of Osteoporosis, vol. 12, no. 1, p. 14, 2017.
[10] M. B. Moreira, A. G. Ponce, C. E. del Valle, and S. I. Roura, “Inhibitory parameters of essential oils to reduce a foodborne pathogen,” LWT-Food Science and Technology, vol. 38, no. 5, pp. 565–570, 2005.
[11] A. K. Genena, H. Hense, A. Smánia Junior, and S. M. d. Souza, “Rosemary (Rosmarinus officinalis): a study of the composition, antioxidant and antimicrobial activities of extracts obtained with supercritical carbon dioxide,” Ciência e Tecnologia de Alimentos, vol. 28, no. 2, pp. 463–469, 2008.
[12] R. C. Mühlauer, A. Lozano, S. Palacio, A. Reini, and R. Felix, “Common herbs, essential oils, and monoterpenes potently modulate bone metabolism,” Bone, vol. 32, no. 4, pp. 372–380, 2003.
[13] K. Rajkowska, A. Kunicka-Styczyńska, M. Maroszyńska, and M. Dabrowska, “The effect of thyme and tea tree oils on morphology and metabolism of Candida albicans,” Acta Biochimica Polonica, vol. 61, no. 2, pp. 305–310, 2014.
[14] M. Sienkiewicz, M. Łysakowska, E. Kowalczyk et al., “The ability of selected plant essential oils to enhance the action of recommended antibiotics against pathogenic wound bacteria,” Burns, vol. 43, no. 2, pp. 310–317, 2017.
[15] B. M. Newton, “Integrative communications,” in Herbal Medicine, Expanded Commission E Monographs, 2000.
[16] G. Pintore, M. Usai, P. Bradesi et al., “Chemical composition and antimicrobial activity of Rosmarinus officinalis L. oils from Sardinia and Corsica,” Flavour and Fragrance Journal, vol. 17, no. 1, pp. 15–19, 2002.
[17] Y. Saito, A. Shiga, Y. Yoshida, T. Furuhashi, Y. Fujita, and E. Niki, “Effects of a novel gaseous antioxidative system containing a rosemary extract on the oxidation induced by nitrogen dioxide and ultraviolet radiation,” Bioscience, Biotechnology, and Biochemistry, vol. 68, no. 4, pp. 781–786, 2004.
[18] N. Osakbe, A. Yasuda, M. Natsume, and T. Yoshikawa, “Rosmarinic acid inhibits epidermal inflammatory responses: anticarcinogenic effect of Perilla frutescens extract in the murine two-stage skin model,” Carcinogenesis, vol. 25, no. 4, pp. 549–557, 2004.
[19] G. Sancheti and P. K. Goyal, “Effect of Rosmarinus officinalis in modulating 7,12-dimethylbenz(a)anthracene induced skin tumorigenesis in mice,” Phytotherapy Research, vol. 20, no. 11, pp. 981–986, 2006.
[20] M. Gayà, V. Repetto, J. Toneatto, C. Anesini, G. Piwien-Pilpuk, and S. Moreno, “Antidiagnostic effect of canosenic acid, a natural compound present in Rosmarinus officinalis, is exerted through the C/EBPs and PPARy pathways at the onset of the differentiation program,” Biochimica et Biophysica Acta (BBA)-General Subjects, vol. 1830, no. 6, pp. 3796–3806, 2013.
[21] H. El-Zaeddi, J. Martinez-Tomé, Á. Calín-Sánchez, F. Burló, and A. Carbonell-Barrachina, “Volatiles composition of essential oils from different aromatic herbs grown in mediterranean regions of Spain,” Foods, vol. 5, no. 4, p. 41, 2016.
[22] P. G. Reeves, F. H. Nielsen, and G. C. Fahey Jr., “AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet,” Journal of Nutrition, vol. 123, no. 11, pp. 1939–1951, 1993.
[23] A. Shinoki and H. Hara, “Calcium deficiency in the early stages after weaning is associated with the enhancement of a low level of adrenaline-stimulated lipolysis and reduction of adiponectin release in isolated rat mesenteric adipocytes,” *Metabolism*, vol. 59, no. 7, pp. 951–958, 2010.

[24] A. Naemura, M. Ura, T. Yamashita, R. Arai, and J. Yamamoto, “Long-term intake of rosemary and common thyme herbs inhibits experimental thrombosis without prolongation of bleeding time,” *Thrombosis Research*, vol. 122, no. 4, pp. 517–522, 2008.

[25] G. Soliman, “Effect of rosmarinus officinalis on lipid profile of streptozotocin-induced diabetic rats,” *Journal of Research in Diabetes*, vol. 2013, pp. 1–9, 2013.

[26] M. M. Elkomy and F. G. Elsaid, “Anti-osteoporotic effect of medicinal herbs and calcium supplementation on ovarietocimized rats,” *The Journal of Basic and Applied Zoology*, vol. 72, pp. 81–88, 2015.

[27] H. H. Draper and M. Hadley, “[43] Malondialdehyde determination as index of lipid Peroxidation,” *Oxygen Radicals in Biological Systems Part B: Oxygen Radicals and Antioxidants*, vol. 186, pp. 421–431, 1990.

[28] J. D. Bancroft and M. Gamble, *Theory and Practice of Histological Techniques*, Churchill Livingstone, London, UK, 5th edition, 2002.

[29] F. Cosman, S. J. de Beur, M. S. LeBoff et al., “Clinician’s guide to prevention and treatment of osteoporosis,” *Osteoporosis International*, vol. 25, no. 10, pp. 2359–2381, 2014.

[30] V. A. Moyer, “Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement,” *Annals of Internal Medicine*, vol. 158, pp. 691–696, 2013.

[31] A. C. Ross, C. L. Taylor, A. L. Yaktine, and Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, *Dietary Reference Intakes for Calcium and Vitamin D*, National Academies Press, Washington, DC, USA, 2011.

[32] R. Kowalski and J. Wawrzykowska, “Essential oils analysis in dried materials and granulates obtained from *Thymus vulgaris* L., *Salvia officinalis* L., *Mentha piperita* L. and *Chamomilla recutita* L.,” *Flavour and Fragrance Journal*, vol. 24, no. 1, pp. 31–35, 2009.

[33] M. C. Rota, A. Herrera, R. M. Martinez, J. A. Sotomayor, and M. J. Jordán, “Antimicrobial activity and chemical composition of Thymus vulgaris, Thymus zygis and Thymus hemanalis essential oils,” *Food Control*, vol. 19, no. 7, pp. 681–687, 2008.

[34] A. D. Lisi, L. Tedone, V. Montesano, G. Sarli, and D. Negro, “Chemical characterisation of Thymus populations belonging from Southern Italy,” *Food Chemistry*, vol. 125, no. 4, pp. 1284–1286, 2011.

[35] A. G. Pirbalouti, M. Hashemi, and F. T. Ghafrarokhi, “Essential oil and chemical compositions of wild and cultivated *Thymus daenensis* Celak and *Thymus vulgaris* L.” *Industrial Crops and Products*, vol. 48, pp. 43–48, 2013.

[36] O. Boruğa, C. Jianu, C. Mişcă, I. Golęţ, A. T. Gruiu, and F. G. Horhat, “Thymus vulgaris essential oil: chemical composition and antimicrobial activity,” *Journal of Medicine and Life*, vol. 7, no. 3, pp. 56–60, 2014.

[37] Z. Amirghofran, H. Ahmadi, M. H. Karimi, F. Kalantar, N. Gholijani, and Z. Malek-Hosseini, “In vitro inhibitory effects of thymol and carvacrol on dendritic cell activation and function,” *Pharmaceutical Biology*, vol. 54, pp. 1125–1132, 2016.

[38] M. F. Nagoor Meenan, H. Javed, H. Al Taee, S. Azimuthullah, and S. Ojha, “Pharmacological properties and molecular mechanisms of thymol: prospects for its therapeutic potential and pharmaceutical development,” *Front. Pharmacol.*, vol. 8, p. 380, 2017.

[39] H. K. Wei, H. X. Xue, Z. X. Zhou, and J. Peng, “A carvacrol-thymol blend decreased intestinal oxidative stress and influenced selected microbes without changing the messenger RNA levels of tight junction proteins in jejunal mucosa of weaning piglets,” *Animal*, vol. 15, pp. 1–9, 2016.

[40] M. F. Nagoor Meenan, G. S. Jagadeesh, and P. Selvaraj, “Thymol attenuates altered lipid metabolism in β-adrenergic agonist induced myocardial infarcted rats by inhibiting tachycardia, altered electrocardiogram, apoptosis and cardiac hypertrophy,” *Journal of Functional Foods*, vol. 14, pp. 51–62, 2015.

[41] M. F. Nagoor Meenan, G. S. Jagadeesh, and P. Selvaraj, “Thymol, a dietary monoterpene phenol abrogates mitochondrial dysfunction in β-adrenergic agonist induced myocardial infarcted rats by inhibiting oxidative stress,” *Chemico-Biological Interactions*, vol. 244, pp. 139–168, 2016.

[42] C. Boztekedijret, F. Bentahar, R. Belabbes, and J. M. Bessiere, “Extraction of rosemary essential oil by steam distillation and hydrodistillation,” *Flavour and Fragrance Journal*, vol. 18, no. 6, pp. 481–484, 2003.

[43] M. Sienkiewicz, M. Łysakowska, M. Pastuszka, W. Bienias, and E. Kowalczyk, “The potential of use basil and rosemary essential oils as effective antibacterial agents,” *Molecules*, vol. 18, no. 8, pp. 9334–9351, 2013.

[44] S. Prabuseenivasan, M. Jayakumar, and S. Ignacamuthu, “In vitro antibacterial activity of some plant essential oils,” *BMC Complementary and Alternative Medicine*, vol. 6, no. 1, p. 39, 2006.

[45] B. Bozin, N. Mimica-Dukic, I. Samoijlik, and E. Jovic, “Antimicrobial and antioxidant properties of rosemary and sage (*Rosmarinus officinalis* L and *Salvia officinalis* L., Lamiaceae) essential oils,” *Journal of Agricultural and Food Chemistry*, vol. 55, no. 19, pp. 7879–7885, 2007.

[46] U. Juergens, “Anti-inflammatory properties of the monoterpene 1,8-cineole: current evidence for Co-medication in inflammatory airway diseases,” *Drug Research*, vol. 64, no. 12, pp. 638–646, 2014.

[47] L. J. Juergens, K. Racké, I. Tuleta, M. Stoebner, and U. R. Juergens, “Anti-inflammatory effects of 1,8-cineole (eucalyptol) improve glucocorticoid effects in vitro: a novel approach of steroid-sparing add-on therapy for COPD and asthma?,” *Synergy*, vol. 5, pp. 1–8, 2017.

[48] M. Sapkota, L. Li, S.-W. Kim, and Y. Soh, “Thymol inhibits RANKL-induced osteoclastogenesis in RAW264.7 and BMM cells and LPS-induced bone loss in mice,” *Food and Chemical Toxicology*, vol. 120, pp. 418–429, 2018.

[49] C. Tannenbaum, J. Clark, K. Schwartzman et al., “Yield of oxygen radicals from the human lung,” in *The Journal of Basic and Applied Zoology*, vol. 72, pp. 638–646, 2018.

[50] F. G. Horhat, “Thymolol attenuates altered lipid metabolism in β-adrenergic agonist induced myocardial infarcted rats by inhibiting tachycardia, altered electrocardiogram, apoptosis and cardiac hypertrophy,” *Journal of Functional Foods*, vol. 14, pp. 51–62, 2015.

[51] A. J. Yun and P. Y. Lee, “Maladaptation of the link between inflammation and bone turnover may be a key determinant of osteoporosis,” *Medical Hypotheses*, vol. 63, no. 3, pp. 532–537, 2004.
J. R. Arron and Y. Choi, “Bone versus immune system,” Nature, vol. 408, no. 6812, pp. 535–536, 2000.

J. Lorenzo, “Interactions between immune and bone cells: new insights with many remaining questions,” Journal of Clinical Investigation, vol. 106, no. 6, pp. 749–752, 2000.

K. K. Kielb-Glaser, K. J. Preacher, R. C. MacCallum, C. Atkinson, W. B. Malarkey, and R. Glaser, “Chronic stress and age-related increases in the proinflammatory cytokine IL-6,” Proceedings of the National Academy of Sciences, vol. 100, no. 15, pp. 9090–9095, 2003.

K. Ishihara and T. Hirano, “IL-6 in autoimmune disease and chronic inflammatory proliferative disease,” Cytokine and Growth Factor Reviews, vol. 13, no. 4-5, pp. 357–368, 2002.

A. R. Moschen, A. Kaser, B. Enrich et al., “The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss,” Gut, vol. 54, no. 4, pp. 479–487, 2005.

C. Scheidt-Nave, H. Bismar, G. Leidig-Bruckner et al., “Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 2032–2042, 2001.

B. Müller, “Cytokine imbalance in non-immunological chronic disease,” Cytokine, vol. 18, no. 6, pp. 334–339, 2002.

J. M. Koh, Y. H. Kang, C. H. Jung et al., “Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis,” Osteoporosis International, vol. 16, no. 10, pp. 1263–1271, 2005.

K. Ganesan, S. Teklehaimanot, T. H. Tran, M. Asuncion, and K. Norris, “Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females,” Journal of the National Medical Association, vol. 97, pp. 329–33, 2005.

T. Essawi and M. Sour, “Screening of some Palestinian medicinal plants for antibacterial activity,” Journal of Ethnopharmacology, vol. 70, no. 3, pp. 343–349, 2000.

K. Miura, H. Kikuzaki, and N. Nakatani, “Antioxidant activity of chemical components from sage (salvia officinalis L.) and thyme (thymus vulgaris L.) measured by the oil stability index method,” Journal of Agricultural and Food Chemistry, vol. 50, no. 7, pp. 1845–1851, 2002.

K. M. Soliman and R. I. Badeea, “Effect of oil extracted from some medicinal plants on different mycotoxicogenic fungi,” Food and Chemical Toxicology, vol. 40, no. 11, pp. 1669–1675, 2002.

M. Hudaib, E. Speroni, A. M. Di Pietra, and V. Cavrini, “GC/MS evaluation of thyme (Thymus vulgaris L.) oil composition and variations during the vegetative cycle,” Journal of Pharmaceutical and Biomedical Analysis, vol. 29, no. 4, pp. 691–700, 2002.

R. Aeschbach, J. Löliger, B. C. Scott et al., “Antioxidant actions of thymol, carvacrol, 6-geranial, zingerone and hydroxytyrosol,” Food and Chemical Toxicology, vol. 32, no. 1, pp. 31–36, 1994.

P. C. Braga, M. Dal Sasso, M. Culici, T. Bianchi, L. Bordoni, and L. Marabini, “Anti-inflammatory activity of thymol: inhibitory effect on the release of human neutrophil elastase,” Pharmacology, vol. 77, no. 3, pp. 130–136, 2006.

S. Fujisawa and Y. Kadoma, “Effect of phenolic compounds on the polymerization of methyl methacrylate,” Dental Materials, vol. 8, no. 5, pp. 324–326, 1992.

T. Bakirel, U. Bakirel, O. Ü. Keleș, S. G. Ülgen, and H. Yardibi, “In vivo assessment of antidiabetic and antioxidant activities of rosemary (Rosmarinus officinalis) in alloxan-diabetic rabbits,” Journal of Ethnopharmacology, vol. 116, no. 1, pp. 64–73, 2008.

P.-F. Laura, M. T. Garzón, and M. Vicente, “Relationship between the antioxidant capacity and effect of rosemary (Rosmarinus officinalis L.) polyphenols on membrane phospholipid order,” Journal of Agricultural and Food Chemistry, vol. 58, no. 1, pp. 161–171, 2010.

K.-C. Lian, J.-J. Chuang, C.-W. Hsieh et al., “Dual mechanisms of NF-κB inhibition in carnosol-treated endothelial cells,” Toxicology and Applied Pharmacology, vol. 245, no. 1, pp. 21–35, 2010.

V. Domazetovic, M. Gemma, I. Teresa et al., “Oxidative stress in bone remodeling: role of antioxidants,” Clinical Cases in Mineral and Bone Metabolism, vol. 14, no. 2, pp. 209–216, 2017.

Y. Peng, J. Yuan, F. Liu, and J. Ye, “Determination of active components in rosemary by capillary electrophoresis with electrochemical detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 39, no. 3–4, pp. 431–437, 2005.

E. N. Frankel, S.-W. Huang, R. Aeschbach, and E. Prior, “Antioxidant activity of a rosemary extract and its constituents, carnosic acid, carnosol, and rosmanic acid, in bulk oil and oil-in-water emulsion,” Journal of Agricultural and Food Chemistry, vol. 44, no. 1, pp. 131–135, 1996.

R. C. Mühlbauer and F. Li, “Effect of vegetables on bone metabolism,” Nature, vol. 401, no. 6751, pp. 343–344, 1999.

H. N. Rosen, R. Dresner-Pollak, A. C. Moses et al., “Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover,” Calcified Tissue International, vol. 54, no. 1, pp. 26–29, 1994.

B. J. Gertz, P. Shao, D. A. Hanson et al., “Monitoring bone resorption in early postmenopausal women by an immunosassay for cross-linked collagen peptides in urine,” Journal of Bone and Mineral Research, vol. 9, no. 2, pp. 35–42, 1994.

T. Berlin and I. Björkhem, “On the regulatory importance of 1,25-dihydroxyvitamin D3 and dietary calcium on serum levels of 25-hydroxyvitamin D3 in rats,” Biochemical and Biophysical Research Communications, vol. 144, pp. 1055–1058, 1987.

T. Berlin and I. Björkhem, “Effect of calcium intake on serum levels of 25-hydroxyvitamin D3,” European Journal of Clinical Investigation, vol. 18, no. 1, pp. 52–55, 1988.

D. L. Akelel, A. S. Germain, C. T. Peterson, K. B. Hanson, J. W. Stewart, and T. Toda, “Isolavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women,” The American Journal of Clinical Nutrition, vol. 72, no. 3, pp. 844–852, 2000.

K. D. Setchell and E. Lydeking-Olsen, “ Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies,” The American Journal of Clinical Nutrition, vol. 78, no. 3, pp. 593S–609S, 2003.

J. R. Hunt, C. A. Zito, J. P. Idso, and L. K. Johnson, “Calcium requirements of growing rats based on bone mass, structure, or biomechanical strength are similar,” Journal of Nutrition, vol. 138, no. 8, pp. 1462–1468, 2008.

M. Tezval, A. Banhardt, S. Sehmisch et al., “The effects of parathyroid hormone applied at different regimes on the trochanteric region of the femur in ovariectomized rat model of osteoporosis,” Journal of Osteoporosis, vol. 2011, p. 363617, 2011.

M. Tezval, G. Serferaž, T. Rack et al., “Effect of parathyroid hormone on hypogonadism induced bone loss of proximal
femur of orchiectomized rat,” *World Journal of Urology*, vol. 29, no. 4, pp. 529–534, 2011.

[84] T. Kim, H. Ha, N. Kim et al., “ATP6v0d2 deficiency increases bone mass, but does not influence ovariectomy-induced bone loss,” *Biochemical and Biophysical Research Communications*, vol. 403, no. 1, pp. 73–78, 2010.
